Novo Nordisk A/S
novonordisk.comWhat Do They Do?
Manufactures and markets medicines for people with obesity, diabetes and rare diseases.
20-F for FY2025, filed Feb 4, 2026Novo Nordisk is a global healthcare company and a world leader in Obesity and Diabetes care. The Company manufactures and markets…View ↗
The Company has a broad product portfolio across Obesity and Diabetes care and Rare disease, including a portfolio of…View ↗
During 2025, there have been periodic supply constraints for certain products in some markets, including the leading product by sales…View ↗
Who Are Their Customers?
Its pharmaceutical products are marketed and distributed through subsidiaries, distributors and independent agents, each responsible for specific geographic areas.
20-F for FY2025, filed Feb 4, 2026Novo Nordisk’s pharmaceutical products are marketed and distributed through subsidiaries, distributors and independent agents each…View ↗
How Are They Changing?
Obesity medicines
The older report described Saxenda and Wegovy as its obesity medicines; the latest report also describes Wegovy Pill, which launched recently.
20-F for FY2022, filed Feb 1, 2023 20-F for FY2025, filed Feb 4, 2026The Company markets two drugs - Saxenda® and Wegovy® - for the treatment of people with obesity. In December 2021, Novo Nordisk announced…View ↗
During 2025, there have been periodic supply constraints for certain products in some markets, including the leading product by sales…View ↗
Who Do They Compete With?
Competes with Eli Lilly
20-F for FY2025, filed Feb 4, 2026Due to the increasing number of people with diabetes, the global pharmaceutical market for treatment of diabetes continues to grow. Several…View ↗
Loading...
